Glycogen storage disease type II overview: Difference between revisions
Vellayat Ali (talk | contribs) No edit summary |
Vellayat Ali (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Glycogen storage disease type II}} | {{Glycogen storage disease type II}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{VA}} | ||
{{ | |||
==Overview== | ==Overview== |
Revision as of 18:28, 5 January 2018
Glycogen storage disease type II Microchapters |
Differentiating Glycogen storage disease type II from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glycogen storage disease type II overview On the Web |
American Roentgen Ray Society Images of Glycogen storage disease type II overview |
Directions to Hospitals Treating Glycogen storage disease type II |
Risk calculators and risk factors for Glycogen storage disease type II overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vellayat Ali M.B.B.S[2]
Overview
Glycogen storage disease type II (also called Pompe disease or acid maltase deficiency) is a rare genetic disorder caused by a deficiency in the enzyme acid alpha-glucosidase (GAA) (EC 3.2.1.20 ), which is needed to break down glycogen, a stored form of sugar used for energy. It is the only glycogen storage disease with a defect in lysosomal metabolism.